Blog Archives

Pembrolizumab (Keytruda): Clinical trials on hold

September 2, 2017 – The American Food & Drug Administration (FDA) has announced that two clinical trials with Pembrolizumab (Keytruda) in patients with multiple myeloma have been put on hold. The FDA informs the public, health care professionals, and oncology clinical investigators about the risks associated with the use of Pembrolizumab (Keytruda) in combination with dexamethasone and an immunomodulatory agent (Lenalidomide (Revlimid) or Pomalidomide (Pomalyst)) for the treatment of patients with multiple myeloma.

Read more ›

Tags: , , , , , , , , , , ,

Avelumab (Bavencio) approved to treat Merkel Cell Carcinoma (MCC)

March 24, 2017 –  Merkel Cell Carcinoma (MCC) is a rare and highly aggressive form of skin cancer, which, in most cases, is caused by the Merkel Cell Polyomavirus (MCV). So far, patients with diagnosed MCC did not have an approved treatment option.

Read more ›

Tags: , , , , , , , ,

Risk of severe if not fatal skin reactions with Pembrolizumab (Keytruda)

March 21, 2017 – Health Canada just communicated this important safety information: Cases of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) under treatment of patients with Pembrolizumab (Keytruda) have been reported internationally in the clinical trials and post-marketing setting.

Read more ›

Tags: , , , , , ,

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Genes, the social environment, and adolescent smoking September 17, 2019
    Adolescence is a time of dramatic change. It marks a period of significant physical transformation—such as the drive toward sexual maturity. But it can also be a time of considerable psychological change and social experimentation.
  • Cause of rare, fatal disorder in young children pinpointed September 17, 2019
    Scientists at Washington University School of Medicine in St. Louis appear to have solved a decades-long mystery regarding the precise biochemical pathway leading to a fatal genetic disorder in children that results in seizures, developmental regression and death, usually around age 3. Studying a mouse model with the same human illness—called Krabbe disease—the researchers also […]
  • Gene-targeted cancer drugs, slow release overcome resistance September 16, 2019
    Biomedical engineers at Duke University have developed a method to address failures in a promising anti-cancer drug, bringing together tools from genome engineering, protein engineering and biomaterials science to improve the efficacy, accuracy and longevity of certain cancer therapies.
  • Genetic mutation appears to protect some people from deadly MRSA September 16, 2019
    An inherited genetic tendency appears to increase the likelihood that a person can successfully fight off antibiotic-resistant staph infections, according to a study led by Duke Health researchers.
  • Renegade genes caught red handed September 16, 2019
    The guardians of the human genome that work to prevent potentially disease-causing gene expression might not be as effective at their jobs as previously thought, according to new University of Arizona research.
Top